Telbivudine (Tyzeka, Sebivo) is an antiviral agent used in the treatment of hepatitis B infection.

Tedizolid is the active moiety of the prodrug tedizolid phosphate, with high potency against Gram-positive species.

Tecalcet (R-568.

Tecalcet (R-568.

Tebanicline hydrochloride (ABT594 hydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to α4β2 neuronal nAChRs with a Ki of 37 pM.

TDI-2760 si a small molecule Aβ-aggregation inhibitor that not only shows a strong inhibitory efficacy toward the Aβ-fibrinogen interaction (IC50=1.67 uM) but also retains potency toward the Aβ42 aggregation inhibition process.

TD-6450 is a next generation, potent HCV NS5A inhibitor that has potent antiviral activity against HCV infection..

TCN238 is a positive allosteric mGlu4 receptor modulator with an EC50 of 1 μM.

TCID is a selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor with IC50 of 0.6 uM, displays >100-fold selectivity over UCH-L1.

TCASK10 is a potent, highly specific inhibitor of ASK1 with IC50 of 14 nM, 30-fold selectivity over ASK2 (IC50=510 nM) and no activity against MEKK1, TAK1, IKKβ, ERK1, JNK1, p38α, GSK-3β, PKCθ and B-raf.

TBZE-029 is a selective inhibitor of the replication of several Enteroviruses with IC50 of 1.2 uM against coxsackievirus B3 replication, targets nonstructural protein 2C..

TBOPP is a selective inhibitor of Rac-specific guanine nucleotide exchange factor DOCK1, inhibits DOCK1-mediated Rac activation with IC50 of 8.4 uM.

TBK1-IKKε inhibitor II is a potent, selective dual inhibitor of TBK1/IKKε with IC50 of 13 nM/59 nM, respectively.

tBID is a selective inhibitor of homeodomain–interacting protein kinase 2 (HIPK2) with an IC50 of  0.33 µM.

TBA-354 is a potent anti-tuberculosis compound; maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug-sensitive and drug-resistant isolates.

TASP0376377 is a potent, selective prostaglandin D2 receptor (CRTH2) antagonist with binding IC50 of 19 nM.

Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertensionFor the detailed information of Tasosartan, the solubility of Tasosartan in water, the solubility of Tasosartan in DMSO, the solubility of Tasosartan in PBS buffer, the animal experiment (test) of Tasosartan, the cell expriment (test) of Tasosartan, the in vivo, in vitro and clinical trial test of Tasosartan, the EC50, IC50,and Affinity of Tasosartan, Please contact DC Chemicals..

Tasisulam (LY 573636) is a small molecule antitumor agent that induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death.

TAS-117 is a potent, selective, allosteric inhibitor of Akt with IC50 of 4.8/1.6/44 for Akt1/2/3, respectively.

TAS-114 is a first-in-class, potent, dual dUTPase/DPD inhibitor with Ki of 0.13/2.14 uM, respectively.

TAS-103(BMS-247615) is a dual inhibitor of topoisomerase-I (topo-I) and topoisomerase-II (topoII).

TAS05567 (TAS-5567) is a novel potent, selective, orally available Spleen tyrosine kinase (Syk) inhibitor with IC50 of 0.37 nM.

Taranabant is a highly selective cannabinoid-1 (CB1) receptor inverse agonist.

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

Tarafenacin(SVT-40776) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor.

TAPI-1 is a specific TACE(TNF-α-converting enzyme) inhibitor.

TAP-311 is a novel potent and selective CETP inhibitor with plasma IC50 of 62 nM.

TAOK inhibitor 63 is a novel potent, selective, ATP-competitive TAO Kinase (TAOK) inhibitor with IC50 of 19 and 39 nM against TAOK1 (MAP3K16) and TAOK2 (MAP3K17), respectively.

Tanomastat is an angiogenesis and Matrix Metalloproteinase inhibitor

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2.